{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:50:12Z","timestamp":1767340212918,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.jaad.2003.09.005","type":"journal-article","created":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T11:12:07Z","timestamp":1079781127000},"page":"600-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study"],"prefix":"10.1016","volume":"50","author":[{"given":"Narin","family":"Apisarnthanarax","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhshandra","family":"Talpur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staci","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2003.09.005_BIB1","first-page":"276","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2003.09.005_BIB2","doi-asserted-by":"crossref","unstructured":"Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 1996;132:1309-13","DOI":"10.1001\/archderm.1996.03890350051009"},{"key":"10.1016\/j.jaad.2003.09.005_BIB3","doi-asserted-by":"crossref","unstructured":"Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135:26-32","DOI":"10.1001\/archderm.135.1.26"},{"key":"10.1016\/j.jaad.2003.09.005_BIB4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2003.09.005_BIB5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0733-8635(05)70312-0","article-title":"CTCL","volume":"19","author":"Apisarnthanarax","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2003.09.005_BIB6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14737140.1.3.403","article-title":"Therapy options in cutaneous T-cell lymphoma","volume":"1","author":"Apisarnthanarax","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jaad.2003.09.005_BIB7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","article-title":"Treatment of cutaneous T cell lymphoma","volume":"3","author":"Apisarnthanarax","year":"2002","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2003.09.005_BIB8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1365-2133.1999.140S54012.x","article-title":"Novel retinoids with receptor selectivity and functional selectivity","volume":"140","author":"Johnson","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2003.09.005_BIB9","doi-asserted-by":"crossref","unstructured":"Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92","DOI":"10.1016\/S0190-9622(97)70216-0"},{"key":"10.1016\/j.jaad.2003.09.005_BIB10","unstructured":"Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle controlled study. Cutis 1999;63:349-54"},{"key":"10.1016\/j.jaad.2003.09.005_BIB11","doi-asserted-by":"crossref","unstructured":"Peris K. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999;341:1767-8","DOI":"10.1056\/NEJM199912023412312"},{"key":"10.1016\/j.jaad.2003.09.005_BIB12","doi-asserted-by":"crossref","unstructured":"Sefton J, Kligman AM, Kopper SC, Lue JC, Gibson JR. Photodamage pilot study: a double-blind, vehicle controlled study to assess the efficacy and safety of tazarotene 0.1% gel. J Am Acad Dermatol 2000;43:656-63","DOI":"10.1067\/mjd.2000.107938"},{"key":"10.1016\/j.jaad.2003.09.005_BIB13","doi-asserted-by":"crossref","unstructured":"Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32","DOI":"10.1001\/archderm.138.3.325"},{"key":"10.1016\/j.jaad.2003.09.005_BIB14","unstructured":"Heald P, Mehlmauer M, Martin A, Olsen E, Worldwide Bexarotene Study Group, Crowley C, et al. The benefits of topical bexarotene (Targretin) in patients with refractory or persistent early stage CTCL [abstract]. J Invest Dermatol 2000;114:840"},{"key":"10.1016\/j.jaad.2003.09.005_BIB15","unstructured":"Duvic M, Martin A, Kim Y, Olsen E, Wood G, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93"},{"key":"10.1016\/j.jaad.2003.09.005_BIB16","doi-asserted-by":"crossref","unstructured":"Duvic M, Hymes K, Heald P, Martin AG, Myskowski P, Crowley C, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"10.1016\/j.jaad.2003.09.005_BIB17","unstructured":"Conover WJ. Practical non-parametric statistics. 2nd ed. New York: Wiley; 1980"},{"key":"10.1016\/j.jaad.2003.09.005_BIB18","unstructured":"Vonesh EF, Chinchilli VM. Linear and non-linear models for analysis of repeated measures. New York: Marcel Dekker; 1977"},{"issue":"Suppl","key":"10.1016\/j.jaad.2003.09.005_BIB19","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0190-9622(97)80396-9","article-title":"Molecular mechanisms of tazarotene action in psoriasis","volume":"37","author":"Duvic","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2003.09.005_BIB20","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0190-9622(98)70309-3","article-title":"The pathogenesis of psoriasis and the mechanism of action of tazarotene","volume":"39","author":"Duvic","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.09.005_BIB21","doi-asserted-by":"crossref","unstructured":"Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003;121:902-9","DOI":"10.1046\/j.1523-1747.2003.12488.x"},{"key":"10.1016\/j.jaad.2003.09.005_BIB22","unstructured":"Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune response. Clin Cancer Res 2001;7:2682-92"},{"key":"10.1016\/j.jaad.2003.09.005_BIB23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper-T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2003.09.005_BIB24","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/S0190-9622(98)70311-1","article-title":"Tazarotene in combination with topical corticosteroids","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.09.005_BIB25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.09.005_BIB26","unstructured":"Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma (CTCL) cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203032961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203032961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:30:05Z","timestamp":1759267805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203032961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0190962203032961"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2003.09.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2003.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}